JP7373176B2 - 皮膚の酵素活性を制御する分子的細菌療法 - Google Patents

皮膚の酵素活性を制御する分子的細菌療法 Download PDF

Info

Publication number
JP7373176B2
JP7373176B2 JP2020511758A JP2020511758A JP7373176B2 JP 7373176 B2 JP7373176 B2 JP 7373176B2 JP 2020511758 A JP2020511758 A JP 2020511758A JP 2020511758 A JP2020511758 A JP 2020511758A JP 7373176 B2 JP7373176 B2 JP 7373176B2
Authority
JP
Japan
Prior art keywords
skin
activity
aureus
staphylococcus
hominis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536494A (ja
Inventor
ギャロ、リチャード、エル
ウィリアムズ、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020536494A publication Critical patent/JP2020536494A/ja
Priority to JP2023177929A priority Critical patent/JP7720639B6/ja
Application granted granted Critical
Publication of JP7373176B2 publication Critical patent/JP7373176B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/44—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/44—Staphylococcus
    • C12R2001/45—Staphylococcus epidermidis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020511758A 2017-08-31 2018-08-31 皮膚の酵素活性を制御する分子的細菌療法 Active JP7373176B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177929A JP7720639B6 (ja) 2017-08-31 2023-10-14 皮膚の酵素活性を制御する分子的細菌療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553025P 2017-08-31 2017-08-31
US62/553,025 2017-08-31
PCT/US2018/049237 WO2019046801A1 (en) 2017-08-31 2018-08-31 MOLECULAR BACTERIOTHERAPY FOR CONTROLLING THE ENZYMATIC ACTIVITY OF THE SKIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177929A Division JP7720639B6 (ja) 2017-08-31 2023-10-14 皮膚の酵素活性を制御する分子的細菌療法

Publications (2)

Publication Number Publication Date
JP2020536494A JP2020536494A (ja) 2020-12-17
JP7373176B2 true JP7373176B2 (ja) 2023-11-02

Family

ID=65527832

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511758A Active JP7373176B2 (ja) 2017-08-31 2018-08-31 皮膚の酵素活性を制御する分子的細菌療法
JP2023177929A Active JP7720639B6 (ja) 2017-08-31 2023-10-14 皮膚の酵素活性を制御する分子的細菌療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177929A Active JP7720639B6 (ja) 2017-08-31 2023-10-14 皮膚の酵素活性を制御する分子的細菌療法

Country Status (10)

Country Link
US (2) US20210177917A1 (https=)
EP (1) EP3675884A4 (https=)
JP (2) JP7373176B2 (https=)
KR (1) KR20200083435A (https=)
CN (1) CN111295196A (https=)
AU (1) AU2018326791B2 (https=)
BR (1) BR112020003508A2 (https=)
CA (1) CA3072772A1 (https=)
MX (1) MX2020002013A (https=)
WO (1) WO2019046801A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072899B1 (en) * 2015-03-23 2018-05-02 Eberhard Karls Universität Tübingen Novel anti-infective compound
JP7678518B2 (ja) * 2019-06-21 2025-05-16 ポーラ化成工業株式会社 スタフィロコッカス・ホミニス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｈｏｍｉｎｉｓ）を有効成分とする肌状態改善剤
KR102286076B1 (ko) * 2019-09-27 2021-08-05 코스맥스 주식회사 스타필로코커스 갈리나룸 st-4 균주 및 그의 피부 상태 개선 용도
KR102199065B1 (ko) * 2019-09-27 2021-01-06 코스맥스 주식회사 스타필로코커스 코니이 st-3 균주 및 그의 피부 상태 개선 용도
KR102195998B1 (ko) * 2019-09-27 2020-12-29 코스맥스 주식회사 스타필로코커스 시뮬란스 st-9 균주 및 그의 피부 상태 개선 용도
KR102195995B1 (ko) * 2019-09-27 2020-12-29 코스맥스 주식회사 스타필로코커스 슐레이페리 st-13 균주 및 그의 피부 상태 개선 용도
KR102199062B1 (ko) * 2019-09-27 2021-01-06 코스맥스 주식회사 스타필로코커스 자일로서스 st-10 균주 및 그의 피부 상태 개선 용도
KR102195996B1 (ko) * 2019-09-27 2020-12-29 코스맥스 주식회사 스타필로코커스 와르네리 st-12 균주 및 그의 피부 상태 개선 용도
KR102286075B1 (ko) * 2019-09-27 2021-08-05 코스맥스 주식회사 스타필로코커스 렌투스 st-2 균주 및 그의 피부 상태 개선 용도
KR102286077B1 (ko) * 2019-09-27 2021-08-05 코스맥스 주식회사 스타필로코커스 에피더미디스 st-6 균주 및 그의 피부 상태 개선 용도
KR102233385B1 (ko) * 2019-09-27 2021-03-29 코스맥스 주식회사 스타필로코커스 캐피티스 st-1 균주 및 그의 피부 상태 개선 용도
JP2023512215A (ja) * 2020-01-29 2023-03-24 ザ ジャクソン ラボラトリー 細菌混和物
CN111870225A (zh) * 2020-08-04 2020-11-03 中国科学技术大学 一种用于荧光标定的标准模板制作方法
WO2022087065A1 (en) * 2020-10-21 2022-04-28 The Jackson Laboratory Antimicrobial biosensors
CN112778399A (zh) * 2021-01-21 2021-05-11 南开大学 一类源自毒性淀粉样纤维纳米抗菌肽的制备及性质表征方法
JP2024508541A (ja) * 2021-03-05 2024-02-27 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア 皮膚プロバイオティクス
CN113234125B (zh) * 2021-05-10 2022-12-06 华东理工大学 自组装多肽、多肽水凝胶及其制备方法和用途
CN113730648B (zh) * 2021-09-06 2022-11-01 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用
KR102609655B1 (ko) * 2022-07-27 2023-12-06 코스맥스 주식회사 스트렙토코커스 소브리너스 균주 및 그의 피부 상태 개선 용도
KR102855516B1 (ko) * 2022-06-03 2025-09-08 코스맥스 주식회사 스타필로코커스 아우리큘라리스 균주 및 그의 피부 상태 개선 용도
KR102855517B1 (ko) * 2022-06-03 2025-09-05 코스맥스 주식회사 스타필로코커스 코흐니 균주 및 그의 피부 상태 개선 용도
KR102609656B1 (ko) * 2022-06-03 2023-12-06 코스맥스 주식회사 스타필로코커스 호미니스 균주 및 그의 피부 상태 개선 용도
CN116515662A (zh) * 2022-08-05 2023-08-01 山东福瑞达生物股份有限公司 一株抗炎阿尔莱特葡萄球菌及其应用
WO2024158103A1 (ko) * 2023-01-25 2024-08-02 코스맥스 주식회사 스트렙토코커스 속 균주를 포함하는 피부 질환의 예방, 개선 또는 치료용 조성물
CN116694535B (zh) * 2023-07-20 2024-08-23 四川大学 一种戊糖乳杆菌w19及其应用
WO2025240841A1 (en) * 2024-05-16 2025-11-20 The Regents Of The University Of California Antimicrobial therapy
CN119326709A (zh) * 2024-11-07 2025-01-21 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种表皮葡萄球菌h62-3代谢产物凝胶制剂及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511537A (ja) 1996-05-22 2000-09-05 ニューヨーク・ユニヴァーシティ 黄色ブドウ球菌における毒力因子の発現の阻止
JP2011500814A (ja) 2007-10-25 2011-01-06 ザ スクリプス リサーチ インスティチュート 抗体媒介による細菌のクオラムセンシングの破壊
JP2016535766A (ja) 2013-10-11 2016-11-17 セルヴィシオ ガレゴ デ サウデ（エスイーアールジーエーエス） 弱毒化生ワクチン
JP2017518370A (ja) 2014-05-30 2017-07-06 アジトラ，インコーポレイティド 組換え片利共生皮膚微生物による皮膚疾患の治療処置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US113A (en) 1837-01-31 Improvement in the mode of making or preparing door-plates
US300A (en) 1837-07-29 Machine foe spinning woolen roving
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5464820A (en) 1993-06-22 1995-11-07 The University Hospital Specific inhibitors of tissue kallikrein
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
WO2007001982A1 (en) * 2005-06-20 2007-01-04 Archer-Daniels-Midland Company Altered glyoxylate shunt for improved production of aspartate-derived amino acids and chemicals
AU2006286497A1 (en) * 2005-08-31 2007-03-08 Serentis Limited Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with Staphylococcus aureus
EP2374813A1 (en) * 2008-12-03 2011-10-12 Proyecto de Biomedicina Cima, S.L. Use of phenol-soluble modulins for vaccine development
US20120064125A1 (en) * 2009-04-17 2012-03-15 Horswill Alexander R Agr-mediated inhibition of methicillin resistant staphylococcus aureus
WO2015106175A1 (en) * 2014-01-10 2015-07-16 The Regents Of The University Of California Skin probiotic
US10138282B2 (en) * 2014-05-27 2018-11-27 Indiana University Research And Technology Corporation Peptide antagonist of LL-37
US20200308230A1 (en) * 2016-05-01 2020-10-01 Wisconsin Alumni Research Foundation Peptidic Modulators of Quorum Sensing in Staphylococcus Epidermidis
US20200289611A1 (en) * 2016-05-13 2020-09-17 Cedric Pearce Methods and Compositions for the Inhibition of Quorum Sensing in Bacterial Infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511537A (ja) 1996-05-22 2000-09-05 ニューヨーク・ユニヴァーシティ 黄色ブドウ球菌における毒力因子の発現の阻止
JP2011500814A (ja) 2007-10-25 2011-01-06 ザ スクリプス リサーチ インスティチュート 抗体媒介による細菌のクオラムセンシングの破壊
JP2016535766A (ja) 2013-10-11 2016-11-17 セルヴィシオ ガレゴ デ サウデ（エスイーアールジーエーエス） 弱毒化生ワクチン
JP2017518370A (ja) 2014-05-30 2017-07-06 アジトラ，インコーポレイティド 組換え片利共生皮膚微生物による皮膚疾患の治療処置

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Frontiers in Microbiology，2016年，Vol. 7, Article 1733，pp. 1-13
Infect. Immun.，2001年，Vol. 69, No. 3，pp. 1957-1960
Jpn. J. Lactic Acid Bact.，2010年，Vol. 21, No. 2，pp. 95-106

Also Published As

Publication number Publication date
US20240325460A1 (en) 2024-10-03
BR112020003508A2 (pt) 2020-09-01
AU2018326791A1 (en) 2020-02-27
EP3675884A4 (en) 2021-08-11
EP3675884A1 (en) 2020-07-08
AU2018326791B2 (en) 2023-12-07
JP7720639B2 (ja) 2025-08-08
JP7720639B6 (ja) 2025-09-18
WO2019046801A1 (en) 2019-03-07
CA3072772A1 (en) 2019-03-07
JP2020536494A (ja) 2020-12-17
JP2024009974A (ja) 2024-01-23
MX2020002013A (es) 2020-07-13
KR20200083435A (ko) 2020-07-08
CN111295196A (zh) 2020-06-16
US20210177917A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7720639B6 (ja) 皮膚の酵素活性を制御する分子的細菌療法
JP6947888B2 (ja) クロストリジウム・ヒストリチクム（ｃｌｏｓｔｒｉｄｉｕｍ ｈｉｓｔｏｌｙｔｉｃｕｍ）酵素およびその使用のための方法
US12091652B2 (en) Ammonia-oxidizing Nitrosomonas eutropha strain D23
Leech et al. Toxin-triggered interleukin-1 receptor signaling enables early-life discrimination of pathogenic versus commensal skin bacteria
KR101885403B1 (ko) 신규 락트산 박테리아 및 그를 함유하는 조성물
JP7624219B2 (ja) ニキビの治療のためのプロピオニバクテリウム・アクネスに対する細菌療法
JP2024009822A (ja) 組換え微生物を用いて炎症性皮膚疾患を処置するための方法および組成物
Nakatsuji et al. Competition between skin antimicrobial peptides and commensal bacteria in type 2 inflammation enables survival of S. aureus
EP3720458A1 (en) Methods and compositions to prevent microbial infection
CN111050850A (zh) 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法
US11318176B2 (en) Topical composition, pharmaceutical composition containing inactivated culture and method of facilitating wound healing and scar reduction using the same
Ip et al. Changes of angiotensin-converting enzyme activity in the pancreas of chronic hypoxia and acute pancreatitis
Leyva-Castillo et al. Allergic skin inflammation and S. aureus skin colonization are mutually reinforcing
HK40030376A (en) Molecular bacteriotherapy to control skin enzymatic activity
EP2245149B1 (en) Peptides, compositions, and uses thereof
WO2015196829A1 (zh) 蛋白酶k在皮肤保健和化妆品领域中的应用
Lyu et al. Skin microbiome engineering: Challenges and opportunities in skin diseases treatment
EP4680718A1 (en) Skin archaea preparation
CA3237750A1 (en) Microbial compositions for the treatment of skin diseases
US20210169985A1 (en) Methods for treating gram positive bacterial infection
Rustad et al. Molecular mechanisms of dormancy and resuscitation
Kotwal et al. Case Letter

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230920

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231014

R150 Certificate of patent or registration of utility model

Ref document number: 7373176

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150